In late 2019, reports of a novel coronavirus sparked international concern among the scientific community. Within months, SARS-CoV-2 had spread to nearly every continent, shutting down entire cities and countries and igniting a global effort to find a vaccine that could stop the virus from impacting more damage.
Since then, the COVID-19 pandemic has stretched global healthcare systems and posed a critical challenge for governments, healthcare authorities, health professionals and the industries supporting the healthcare infrastructure.
Whether directly or indirectly, COVID-19 has had a drastic and oftentimes devastating impact on the lives of people worldwide. Restrictions and isolation have placed people under great stress where limited access to healthcare continues to take a severe toll on mental health leading to increased anxiety and fear.
Throughout our more than 130-year history, Johnson & Johnson has a legacy of responding during crisis. We have actively engaged in fighting global outbreaks from tuberculosis to HIV and Ebola. Our knowledge and experience, successes and setbacks alike inform everything we have done to tackle COVID-19.
Johnson & Johnson moved swiftly, mobilizing our research teams, establishing key partnerships and collaborations, and committing to put every resource at the Company's disposal to develop a vaccine to help combat the pandemic. In just over a year, our dedication came to fruition with the delivery of a COVID-19 vaccine candidate at a not-for-profit price that has been approved for emergency use as a single-dose injection in countries around the world. Taking into account issues of access, equity, supply chain infrastructure and the varied needs of a global population, we are providing an important component to a worldwide vaccination strategy for a virus unlike anything we’ve seen in a century.
While our global efforts have focused on combating the COVID-19 pandemic and ensuring care for those directly affected, the need to maintain healthcare for those with other medical conditions while also providing support for those feeling the social, economic and mental health impacts of the pandemic has been equally important. We have leveraged the full scale of our science, capabilities, expertise and team of more than 136,000 compassionate colleagues to address the many different facets of one of the most significant healthcare crises in our history.
Structuring our COVID-19 response: From the outset, Johnson & Johnson formed a dedicated Global Pandemic Crisis Management Team to combat and mitigate the negative impact of the COVID-19 pandemic on our business. More than 50 global cross-functional teams with representation at all levels worked together to make the best decisions for their local geography while driving global alignment and consistency.
COVID-19 Pandemic Governance: Structure and Roles
- Enterprise oversight, strategic direction and approvals
- 30 subject matter experts in relief and emergency supplies, employee well-being and support, travel and security, facility opening readiness, communications and clinical services
- Global guidance and governance
- Global standards for employee protection and business continuity
- Providing resources in support of our business and our people
- Formed at a regional/country level to coordinate response and recovery
- Operational coordination and regional alignment
- Local teams formed at site level to manage site responses to a business continuity question
- Pandemic plan execution
- Facilities management in accordance with global guidelines
- Local communications and leadership/employee engagement
- Local feedback
See here for the most recent updates on our continued efforts to address the COVID-19 pandemic.
In this section:
We describe the main elements of how we are united in defeating COVID-19 under four themes: